macluraxanthone B: from the plant Maclura tinctoria; structure in first source
macluraxanthone B : A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3, 6 and 7, a dimethylallyl group at position 2 and a prenyl group at position 4. Isolated from Maclura tinctoria and Cudrania tricuspidata, it exhibits anti-HIV and antineoplastic activity.
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Maclura | genus | A plant genus of the family MORACEAE. Members contain maclurin, antifungal chalcones, and other compounds.[MeSH] | Moraceae | The mulberry plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. They have milky latex and small, petalless male or female flowers.[MeSH] |
Maclura tinctoria | species | [no description available] | Moraceae | The mulberry plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. They have milky latex and small, petalless male or female flowers.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 5353737 |
CHEMBL ID | 370126 |
CHEBI ID | 66649 |
MeSH ID | M0378339 |
Synonym |
---|
nsc692942 |
chloroxanthone a |
2-(1,1-dimethylallyl)-1,3,6,7-tetrahydroxy-4-(3-methylbut-2-enyl)xanthen-9-one |
macluraxanthone b |
2-(1,1-dimethyl-allyl)-1,3,6,7-tetrahydroxy-4-(3-methyl-but-2-enyl)-xanthen-9-one |
nsc-692942 |
chebi:66649 , |
CHEMBL370126 , |
1,3,6,7-tetrahydroxy-2-(2-methylbut-3-en-2-yl)-4-(3-methylbut-2-enyl)xanthen-9-one |
1,3,6,7-tetrahydroxy-4-(3-methylbut-2-enyl)-2-(2-methylbut-3-en-2-yl)-9h-xanthen-9-one |
2,3,6,8-tetrahydroxy-5-(3-methylbut-2-enyl)-7-(2-methylbut-3-en-2-yl)-9h-xanthen-9-one |
bdbm50175012 |
1,3,6,7-tetrahydroxy-2-(2-methylbut-3-en-2-yl)-4-(3-methylbut-2-en-1-yl)-9h-xanthen-9-one |
Q27135267 |
Role | Description |
---|---|
metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
anti-HIV agent | An antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus. |
antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
xanthones | Any member of the class of xanthenes based on a xanthone skeleton. |
phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Sterol O-acyltransferase 2 | Homo sapiens (human) | IC50 (µMol) | 112.0000 | 0.1100 | 3.2036 | 9.2000 | AID276035 |
Sterol O-acyltransferase 1 | Homo sapiens (human) | IC50 (µMol) | 96.0000 | 0.0250 | 1.7975 | 8.0000 | AID276034 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
fatty-acyl-CoA binding | Sterol O-acyltransferase 2 | Homo sapiens (human) |
sterol O-acyltransferase activity | Sterol O-acyltransferase 2 | Homo sapiens (human) |
protein binding | Sterol O-acyltransferase 2 | Homo sapiens (human) |
cholesterol binding | Sterol O-acyltransferase 2 | Homo sapiens (human) |
acyltransferase activity | Sterol O-acyltransferase 2 | Homo sapiens (human) |
cholesterol O-acyltransferase activity | Sterol O-acyltransferase 2 | Homo sapiens (human) |
fatty-acyl-CoA binding | Sterol O-acyltransferase 1 | Homo sapiens (human) |
sterol O-acyltransferase activity | Sterol O-acyltransferase 1 | Homo sapiens (human) |
protein binding | Sterol O-acyltransferase 1 | Homo sapiens (human) |
cholesterol binding | Sterol O-acyltransferase 1 | Homo sapiens (human) |
cholesterol O-acyltransferase activity | Sterol O-acyltransferase 1 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
endoplasmic reticulum | Sterol O-acyltransferase 2 | Homo sapiens (human) |
endoplasmic reticulum membrane | Sterol O-acyltransferase 2 | Homo sapiens (human) |
brush border | Sterol O-acyltransferase 2 | Homo sapiens (human) |
endoplasmic reticulum membrane | Sterol O-acyltransferase 2 | Homo sapiens (human) |
endoplasmic reticulum | Sterol O-acyltransferase 1 | Homo sapiens (human) |
endoplasmic reticulum membrane | Sterol O-acyltransferase 1 | Homo sapiens (human) |
membrane | Sterol O-acyltransferase 1 | Homo sapiens (human) |
endoplasmic reticulum membrane | Sterol O-acyltransferase 1 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID257307 | Hydroxyl radical scavenging activity of Cudriana tricuspidata extracts | 2005 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24 | Antioxidant and cytotoxic activities of xanthones from Cudrania tricuspidata. |
AID257309 | Cytotoxicity against human cancer HL60 cell line by MTT assay | 2005 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24 | Antioxidant and cytotoxic activities of xanthones from Cudrania tricuspidata. |
AID257311 | Cytotoxicity against human cancer AGS cell line by MTT assay | 2005 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24 | Antioxidant and cytotoxic activities of xanthones from Cudrania tricuspidata. |
AID257310 | Cytotoxicity against human cancer SKOV3 cell line by MTT assay | 2005 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24 | Antioxidant and cytotoxic activities of xanthones from Cudrania tricuspidata. |
AID378244 | Cytotoxicity against human CEM-SS cells | 2000 | Journal of natural products, Nov, Volume: 63, Issue:11 | HIV-Inhibitory prenylated xanthones and flavones from Maclura tinctoria. |
AID276034 | Inhibition of human ACAT1 expressed in Hi5 cells | 2006 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21 | Anti-atherosclerotic and anti-inflammatory activities of catecholic xanthones and flavonoids isolated from Cudrania tricuspidata. |
AID1169597 | Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell viability | 2014 | Journal of natural products, Nov-26, Volume: 77, Issue:11 | Antiproliferative prenylated xanthones and benzophenones from the roots of Cudrania tricuspidata in HSC-T6 cells. |
AID257308 | Cytotoxicity against human cancer HT29 cell line by MTT assay | 2005 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24 | Antioxidant and cytotoxic activities of xanthones from Cudrania tricuspidata. |
AID310609 | Inhibition of bakers yeast alpha-glucosidase by spectrophotometry | 2007 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23 | Xanthones from Cudrania tricuspidata displaying potent alpha-glucosidase inhibition. |
AID276035 | Inhibition of human ACAT2 expressed in Hi5 cells | 2006 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21 | Anti-atherosclerotic and anti-inflammatory activities of catecholic xanthones and flavonoids isolated from Cudrania tricuspidata. |
AID257306 | Superoxide radical scavenging activity of Cudriana tricuspidata extracts | 2005 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24 | Antioxidant and cytotoxic activities of xanthones from Cudrania tricuspidata. |
AID378243 | Antiviral activity against HIV1 | 2000 | Journal of natural products, Nov, Volume: 63, Issue:11 | HIV-Inhibitory prenylated xanthones and flavones from Maclura tinctoria. |
AID378560 | Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Cytotoxic xanthones from Cudrania tricuspidata. |
AID257314 | Cytotoxic activity in HL60 by DNA fragmentation assay | 2005 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24 | Antioxidant and cytotoxic activities of xanthones from Cudrania tricuspidata. |
AID257312 | Cytotoxicity against human cancer A549 cell line by MTT assay | 2005 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24 | Antioxidant and cytotoxic activities of xanthones from Cudrania tricuspidata. |
AID257313 | DPPH radical scavenging activity of Cudriana tricuspidata extracts | 2005 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24 | Antioxidant and cytotoxic activities of xanthones from Cudrania tricuspidata. |
AID378559 | Cytotoxicity against human A549 cells after 48 hrs by SRB assay | 2005 | Journal of natural products, Mar, Volume: 68, Issue:3 | Cytotoxic xanthones from Cudrania tricuspidata. |
AID276033 | Antioxidant activity against human plasma LDL oxidation by TBARS assay | 2006 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21 | Anti-atherosclerotic and anti-inflammatory activities of catecholic xanthones and flavonoids isolated from Cudrania tricuspidata. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (71.43) | 29.6817 |
2010's | 1 (14.29) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.93) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |